Use of drug discovery software for gaining market intelligence owing to several advantages, such as rapid drug design & synthesis, efficient tracking of disease evolution, and data integrity management, has increased significantly among the researchers in the recent years, driving the industry growth.
According to Report, the Drug Discovery Informatics market was valued at US$ 4.39 billion in 2020 and is expected to hit around US$ 6.63 billion by 2030 with a CAGR of 21.3% during forecast period 2021 to 2030.
Growth Factors
Use of drug discovery software for gaining market intelligence owing to several advantages, such as rapid drug design & synthesis, efficient tracking of disease evolution, and data integrity management, has increased significantly among the researchers in the recent years, driving the industry growth.
Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37721
The growing demand for novel molecules is driving the adoption of informatics solutions targeted towards speeding up the entire drug discovery process by identifying rational drug molecules via the target macromolecule interaction. Companies operating in the market are receiving funding for expanding their drug discovery platforms, further supplementing the market growth. For instance, in September 2020, Ardigen signed an agreement with the National Centre for Research and Development to access its funding for developing novel technology.
This technology was aimed at revolutionizing the development of T-cell receptors-based therapies for immuno-oncology. Ardigen has previously developed a neoantigen prediction platform namely, ArdImmune Vax, which deploys ready-to-use (AI) and bioinformatics solutions for the identification of optimal sets of neoantigens as targets for adoptive cell therapies and cancer vaccines. In addition, chemical informatics solutions have gained considerable traction in the past year, particularly in addressing the needs associated with the recent Covid-19 pandemic.
For instance, a research study performed in January 2021 showcased the application of chemical digital solutions in accelerating the search of SARS-CoV-2 Mpro inhibitors by data analysis of previous activity data of SARS-CoV main protease (Mpro) inhibitors. In addition, the QSAR models helped in the data mining of molecules for rapid Covid-19 drug discovery. Hence, the need to facilitate drug development for Covid-19 is expected to propel the industry expansion over the coming years.
| Report Scope | Details |
| Market Size in 2020 | USD 4.39 Billion |
| Growth Rate from 2021 to 2030 | CAGR of 21.3% |
| Largest Market | North America |
| Fastest Growing Region | Asia Pacific |
Report Highlights
The discovery informatics dominated the market in 2020 with a revenue share of 59.19% due to a major focus on the development of precision medicines. involves specific medical care based on the patients’ genetic and molecular profiling. Companies, such as PerkinElmer, Inc., provide discovery informatics solutions for leveraging analytics for rapid drug discovery.
In addition, the governments in several developing countries are promoting the application of for rapid medicine discovery. For instance, in July 2020, the government of India launched Drug Discovery Hackathon (DDH). It is a training program for promoting the discovery of an effective molecule against the Covid-19 virus with the application of drug discovery informatics tools that have potential applications in identification, validation, and designing & molecule synthesis of the lead molecule.
The drug development workflow segment is expected to register the fastest CAGR of 11.69% from 2021 to 2028 owing to an increasing number of medicine candidates in the pipeline for pharmaceutical companies. These tools are used to perform specific tasks in clinical trial designing for promising the greatest improvement of overall trial performance.
The outsourced mode segment dominated the market in 2020 with a revenue share of 51.21%. The segment will expand further at a steady CAGR during the forecast period on account of an increasing number of partnerships between pharmaceutical companies and contract development and manufacturing organizations (CDMOs). Contract Research Organizations (CROs) are involved in the creation of reports on new drug entities that are subsequently used by the sponsor or drug manufacturer for submitting to the U.S. FDA.
There are benefits when pharmaceutical & biotechnology companies partner with a CRO that has the same informatics solution. The shared informatics platform between the CRO and companies helps in monitoring the progress of studies in the same way as their internal studies. This helps the company in cost-saving and productivity gain, which is expected to offer the market entities immense profitable opportunities.
The in-house mode segment is expected to witness the fastest CAGR of 11.73% from 2021 to 2028 due to the increasing adoption of informatics by large-scale companies for drug discovery owing to its advantages, such as providing direct access to information from a wide variety of sources, avoiding lengthy data compilation & reformatting, and helps in combining cross-disciplinary information.
The sequence analysis platforms emerged as a dominant segment with a revenue share of 35.22% in 2020. The segment will retain the dominant position registering the fastest CAGR over the forecast period. Bioinformatic solutions are widely employed for the development of primary & secondary databases of nucleic acid, protein as well as other biomolecule sequences. With the application of informatics software, mining and warehousing of genome sequencing is done for identifying genes and targeted proteins, which will help in the development of potential drugs.
The sequence analysis platforms emerged as a dominant segment with a revenue share of 35.22% in 2020. The segment will retain the dominant position registering the fastest CAGR over the forecast period. Bioinformatic solutions are widely employed for the development of primary & secondary databases of nucleic acid, protein as well as other biomolecule sequences. With the application of informatics software, mining and warehousing of genome sequencing is done for identifying genes and targeted proteins, which will help in the development of potential drugs.
In addition, basic drug discovery research requires the employment of different databases along with sequence analysis tools, such as CLUSTALW, BLAST, and FASTA. Also, the launch of new and advanced software is contributing to the segment growth. For instance, in July 2019, Certara launched a new version of D360, a scientific informatics platform (version 19.6) for drug discovery & development. The platform enables alignment, representation, and analysis of small sections of proteins and peptide sequences.
The informatics platform enables users to arrange peptide sequences based on color code by property. Molecular modeling is increasingly gaining popularity owing to its wide application in the drug discovery process. These tools are applied for the modeling and simulation of biological systems and small molecules for understanding & predicting their behavior at a molecular level. In addition, they accelerate the cost-efficiency of hit discovery and hit-to-lead optimization.
North America accounted for the largest market share of 39.30% in 2020; growth in the region can be attributed to several factors, such as high incidence of infectious diseases, rapid adoption of new & advanced tools for R&D, and the presence of prominent players. Moreover, companies in the region are focusing on joint ventures and research collaborations, which will boost the market growth in the coming years.
Ask here for more details@ https://www.visionresearchreports.com/report/enquiry/37721
Key Players
- Certara
- BoehringerIngelheim International GmbH
- Infosys Ltd.
- Charles River Laboratories
- Collaborative Drug Discovery, Inc.
- Eurofins DiscoverX Products
- Jubilant Biosys
- Selvita
- Novo Informatics Pvt. Ltd.
- ChemAxon Ltd.
- Albany Molecular Research Inc.
- Oracle
- Accenture
- Agilent Technologies, Inc.
- Illumina, Inc.
Market Segmentation
- Workflow Outlook
- Discovery Informatics
- Identification, Validation, & Assay Development Informatics
- Lead Generation
- Development Informatics
- Lead Optimization
- FHD Preparation
- Phase IA
- Phase IB/2
- Discovery Informatics
- Mode Outlook
- Outsourced
- In-house
- Services Outlook
- Sequence Analysis Platforms
- Molecular Modeling
- Docking
- Clinical Trial Data Management
- Other Services
- Regional Outlook
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Click Here to View Full Report Table of Contents
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37721
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333